Value proposition

Using circular RNA to control any gene, in any species, in any cell type. "Acquired by Ginkgo Bioworks in 2022"

Control of any Gene in any Species or Cell Type

Circularis has used the power of circular RNA to develop a novel method to study and regulate gene expression. This technology has enabled increased bio-therapeutic production, improved targeting of gene therapy, and optimized expression in poorly studied organisms. The elegant design and high throughput nature of this technology enables breakthrough solutions without prior knowledge of the regulatory elements or coding sequence.

Gene Expression, Bioprocessing, Molecular Biology, Protein Expression, Drug Discovery, Promoter Discovery, Promoter Enhancement, Metabolic Engineering, Synthetic Biology, Therapeutic Promoters, Biologics, and Gene Therapy